Company Overview and News
Baker Hughes BHGE, +0.62% on Friday reported that the number of active U.S. rigs drilling for oil climbed by 8 to 869 this week. That was the largest weekly rise since the week ended Aug. 10. The oil-rig count had posted declines in each of the past three weeks. The total active U.S. rig count, which includes oil and natural-gas rigs, was also up by 11 at 1,063, according to Baker Hughes. November West Texas Intermediate crude CLX8, +0.
Julianne Geiger is a veteran editor, writer and researcher for US-based Divergente LLC consulting firm, and a member of the Creative Professionals Networking Group.
The University of Strathclyde's Advanced Forming Research Centre (AFRC) and Baker Hughes, a GE company (BHGE), have joined forces to explore how some of the latest advanced manufacturing tools and processes can drive more efficient, smarter ways to reduce cost and increase productivity across BHGE's operations.
PBEGF BHI GEC GE GNE
2018-10-12 investorplace - 1
It has been more than a week since General Electric (NYSE:GE) announced that it had replaced its now-former CEO, John Flannery. GE stock surged nearly 20% in the wake of the announcement before retreating with the rest of the market The dust has yet to fully settle, though, as investors continue weighing the upside of a highly-motivated, new CEO against the plausible reality that fixing GE still won’t be quick, easy or pretty.
BHI GE GEC AAPL BHGE GNE DHR
LAKEWOOD, CO / ACCESSWIRE / October 11, 2018 / General Moly, Inc. (the "Company" or "General Moly") (NYSE American: GMO; TSX: GMO), the only western-exchange listed, pure-play molybdenum mineral development company, reports that molybdenum ("moly") has been a consistent standout among metals during 2018, as the moly price rose 11% against the head winds of retreating base metal and non-energy commodities' prices in 3Q 2018.
GMO BHI GMO
Dril-Quip (NYSE:DRQ) has been range-bound for the past several months and I expect the trend to continue with a bias to the upside going into the earnings call on Oct. 26. Specifically, there are two plays with a slightly bullish bias in DRQ stock that I want to share with you, as each play could lead to impressive profits.
DRQ BHI SPN NOV BHGE
2018-10-09 247wallst - 4
Stocks were looking to open lower on Tuesday after a mixed bag with the Dow Jones industrials rising and S&P 500 and Nasdaq falling on Monday. U.S. equity indexes are still quite close to all-time highs despite the rapid rise in long-term interest rates over the past two weeks. One trend that cannot be ignored is that investors have seen lower upside from buying on market pullbacks than in prior years.
DB RCUS WMT CISN BLKB HOVVB HIG AAPL BOX BRPIF CSX HGH MS HOV LNT HOVNP BHGE BHI INTU DOOO DNKN TRI
2018-10-09 zacks - 2
Subsidiaries of General Electric Company (GE - Free Report) has communicated that those are planning to reshape business portfolios. GE Capital has agreed to sell roughly $1 billion worth of equity investments of its Energy Financial Services business while Baker Hughes, a GE company (BHGE - Free Report) has agreed on purchasing 5% stake in a subsidiary of Abu Dhabi National Oil Company. We believe that the aforementioned news will play a vital role in building positive sentiments for General Electric.
BHI GEC GE MIC BHGE GNE APO
Strategic partnership will expand ADNOC Drilling's capabilities into the integrated drilling and well construction segment and expand BHGE's presence in the UAE
LONDON: Baker Hughes, the world’s second-largest oil services company, will take a 5% stake in Abu Dhabi National Oil Company’s (ADNOC) drilling unit for US$550mil under a tie-up.
BHI GEC GE GNE
ABU DHABI/LONDON (Reuters) - Baker Hughes, the world’s second-largest oil services company, will take a 5 percent stake in Abu Dhabi National Oil Company’s (ADNOC) drilling unit for $550 million under a tie-up announced on Monday.
BHI GEC GE GNE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to BHI / Baker Hughes Inc. on message board site Silicon Investor.
as of ET